ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression - PubMed
5 hours ago
- #ALS
- #glycolysis
- #pyroptosis
- ALDOA promotes glycolysis and NLRP3/GSDMD pyroptosis, accelerating ALS progression.
- ALS model mice showed motor deficits, weight loss, and reduced survival, with elevated ALDOA and L-lactic acid in the motor cortex.
- Aldometanib, an ALDOA inhibitor, suppressed glycolysis, prolonged survival, and slowed disease progression by inhibiting NLRP3/GSDMD-mediated pyroptosis.
- TDP-43-deficient NSC34 cells exhibited increased ALDOA levels, enhanced glycolysis, NLRP3/GSDMD activation, and impaired proliferation.
- ALDOA-mediated glycolytic dysregulation activates NLRP3/GSDMD inflammasome, leading to motor neuron pyroptosis, identifying ALDOA as a potential therapeutic target.